Psychotherapy

YourTango Announces Inaugural YourTango Experts Healers and Helpers Virtual Summit

Retrieved on:

Friday, February 9, 2024

Psychotherapy, Education, Tango (magazine), Hypnotherapy, EST, Loneliness, Mental health, Love, EMDR, Yoga, Knowledge, TED, Nursing

NEW YORK, Feb. 9, 2024 /PRNewswire/ -- Tango Publishing, Inc., creators of YourTango.com and YourTango Experts, a B2B division supporting healing professionals, is thrilled to announce the inaugural Healers and Helpers Summit, a virtual event scheduled for free broadcast from February 14 - 18, 2024. This world-class event offers registrants free access to 24 hours of programming each day beginning at 11:30 a.m. EST. The event aims to inspire and educate a diverse community of healing professionals, providing talks and masterclasses designed to enhance the vital work practitioners do in the areas of mental health, love and relationships, personal growth, and lifestyle wellbeing.

Key Points:

NEW YORK, Feb. 9, 2024 /PRNewswire/ -- Tango Publishing, Inc., creators of YourTango.com and YourTango Experts, a B2B division supporting healing professionals, is thrilled to announce the inaugural Healers and Helpers Summit, a virtual event scheduled for free broadcast from February 14 - 18, 2024.
This world-class event offers registrants free access to 24 hours of programming each day beginning at 11:30 a.m. EST.
YourTango founder and CEO Andrea Miller remarked, "We urgently need to unite around our healing professionals and provide world-class training, education, and support.
By connecting healers and helpers with cutting-edge knowledge and expertise, YourTango reaffirms its commitment to making a positive impact on mental health, relationships, and wellbeing.

GrayMatters Health Announces Pioneering Study Highlighting Safety and Efficacy of Self-Neuromodulation for PTSD

Retrieved on:

Tuesday, February 6, 2024

HAIFA, Israel and NEW YORK, Feb. 6, 2024 /PRNewswire/ -- GrayMatters Health (GMH), developer of digital self-neuromodulation therapies for mental health care, announces the publication of a peer-reviewed article in the Journal of Psychiatry Research demonstrating the safety and efficacy of its FDA-cleared Prism for PTSD device. The prospective, single arm, multi-site, open label trial evaluated men, women, and treatment-resistant combat veterans with chronic post-traumatic stress disorder (PTSD).

Key Points:

The prospective, single arm, multi-site, open label trial evaluated men, women, and treatment-resistant combat veterans with chronic post-traumatic stress disorder (PTSD).
Prism for PTSD is the first self-neuromodulation device to receive FDA clearance as a prescribed adjunct to standard-of-care for PTSD.
The treatment, now available in select clinics in the United States, digitizes brain activity associated with PTSD to scientifically help patients gain control of their PTSD symptoms.
Prism for PTSD uses a computer simulation and EEG headset to create a novel, immersive environment for training individuals to self-modulate an amygdala-based biomarker associated with PTSD.

Clarion Clinics Open for Psychedelic-Assisted Treatments

Retrieved on:

Thursday, February 1, 2024

PTSD, Post-traumatic stress disorder, Clarion, TGA, Prohibition of drugs, Therapeutic Goods Administration, Clinical trial, Environment, Patient, Safety, Depression, Psilocybin, TRD, MDMA, Authorization, Psychotherapy, Schedule, Pharmaceutical industry

MELBOURNE, Australia and NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc (Nasdaq: IXHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet needs is pleased to announce that Clarion Clinic’s co-Founder and Head of Psychiatry, Professor Suresh Sundram, has received Authorised Prescriber approval from the Therapeutic Goods Administration (TGA) to prescribe MDMA in the treatment of Post-traumatic Stress Disorder (PTSD) and psilocybin for Treatment-resistant Depression (TRD) at its first built-for-purpose clinic based in Melbourne, Australia, a city of approximately 5.2M people.

Key Points:

Clarion Clinics’ built-for-purpose clinic in Melbourne is now open for treatment, and will begin screening patients immediately.
Clarion Clinics is a collaboration between Australia’s leading psychedelic-assisted therapy professionals and scientists, and Incannex.
Clarion Clinics, Abbottsford, will be the first dedicated psychedelic-assisted therapy clinic in Australia.
Clarion is at the leading edge of mental healthcare, has the right protocols, and an experienced team ready to help people through these challenging conditions,” Peter Widdows, Incannex Director responsible for Clarion Clinics, said.

VRx Health Launches Xaia on Apple Vision Pro, Combining Spatial Computing and AI for Mental Health Support

Retrieved on:

Friday, February 2, 2024

Psychotherapy, Cognitive behavioral therapy, Apple, AI, Meditation, Research, Motivational interviewing, Mental health, Health, Health care, Health services research, Human

LOS ANGELES, Feb. 2, 2024 /PRNewswire/ -- Today, VRx Health, pioneers of medical extended reality, announced the launch of Xaia (eXtended reality Artificially Intelligent Ally), a first-of-its-kind app combining spatial computing with AI for personalized mental health. Xaia's technology has been exclusively licensed from Cedars-Sinai to VRx Health, to bring immersive AI therapy to the world.

Key Points:

LOS ANGELES, Feb. 2, 2024 /PRNewswire/ -- Today, VRx Health, pioneers of medical extended reality, announced the launch of Xaia (eXtended reality Artificially Intelligent Ally), a first-of-its-kind app combining spatial computing with AI for personalized mental health.
Xaia's technology has been exclusively licensed from Cedars-Sinai to VRx Health, to bring immersive AI therapy to the world.
Currently, Xaia is available as an application on Apple Vision Pro headsets.
Designed to take advantage of the powerful capabilities of visionOS, Xaia is experienced via spatial computing on Vision Pro and visualized as a human-scale, 3D robot.

New Postnatal Retreat Sanu Advances Postpartum Recovery and Support for Families in the Greater Washington D.C. Area

Retrieved on:

Wednesday, January 31, 2024

ICU, Psychiatry, Hygiene, Coterie, Parent, Research, Director of Operations, Psychotherapy, Politics, Caregiver, Safety, Uplift, Lactation, Mental health, Physician, Education, Culture, RN, Nursing

TYSONS, Va., Jan. 31, 2024 /PRNewswire/ -- Sanu, the first physician-developed luxury postnatal retreat providing elevated postpartum recovery and support, has opened at The Watermark Hotel in Tysons, VA. Sanu is currently booking reservations for families welcoming newborns in 2024.

Key Points:

Sanu Postnatal Retreat unites a physician-developed, mother-first program with serene luxury for an exceptional postpartum recovery experience.
TYSONS, Va., Jan. 31, 2024 /PRNewswire/ -- Sanu , the first physician-developed luxury postnatal retreat providing elevated postpartum recovery and support, has opened at The Watermark Hotel in Tysons, VA. Sanu is currently booking reservations for families welcoming newborns in 2024.
Inspired by her Korean roots, Kim has modeled the retreat after South Korea's "Sanhujori" concept of postpartum care centers and the traditional "Sam Chil Il" 21-day healing period.
To support physical and mental health, skill-building, and a comfortable, productive recovery, the Sanu Postnatal Retreat offers evidence-based programming supported by personalized, full-service, round-the-clock care and luxurious comforts for new moms and their families.

Premera Blue Cross, UW Medicine Collaborate on Behavioral Health Integration for Black Communities

Retrieved on:

Tuesday, January 30, 2024

Anxiety, Patient, Premera Blue Cross, Federal Way, Washington, Depression, Hypertension, Mental health, Pacific Northwest, AIMS, Health equity, University, Psychotherapy, Nursing

MOUNTLAKE TERRACE, Wash., Jan. 30, 2024 /PRNewswire/ -- Premera Blue Cross, a health plan in the Pacific Northwest, today announced the company's efforts with the AIMS Center at the University of Washington School of Medicine to improve mental health outcomes for Black and African American communities. Through a $1.4 million investment, three clinics in western Washington will receive funds to implement Collaborative Care, a specific model of integrated care developed at UW Medicine to treat common conditions like depression and anxiety.

Key Points:

Through Collaborative Care, patients can receive care for their mental health in the same setting they are treated for their physical health.
We're grateful to expand our work with UW Medicine to further support integrated care and improve health inequities."
This work builds on a common goal of Premera and UW Medicine to improve mental health outcomes in the Pacific Northwest.
Through this strategy, Premera works to increase equitable healthcare access for Black Washingtonians, Alaska Natives, and rural members to improve their behavioral health and hypertension health outcomes.

Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp

Retrieved on:

Thursday, January 25, 2024

PBM, Commonwealth, Patient, Terminal, Psychotherapy, Special, Health, Global health, Palliative care, Business analyst, Therapeutic Goods Administration, Mental health, Communication, Investment, Acquisition, Psychological trauma, FDA, Projection, Diagnosis

TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (“Psyence Biomed”) is excited to announce the completion of its merger (the “Business Combination”) with Newcourt Acquisition Corp ("Newcourt"), a special purpose acquisition company.

Key Points:

TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (“Psyence Biomed”) is excited to announce the completion of its merger (the “Business Combination”) with Newcourt Acquisition Corp ("Newcourt"), a special purpose acquisition company.
The Note Financing will be utilized to further Psyence Biomed’s clinical trials conducted in Australia.
The Business Combination received approval from Newcourt's stockholders at a Special Meeting held on January 18, 2024.
Psyence Biomed anticipates that the NASDAQ listing will raise Psyence Biomed’s profile, attracting additional investments to support its vision of transforming the health and wellness sector.

Being Health Launches With $5.4 Million in Funding and a Mission to Bring the Best of Psychiatry and Novel Treatments Under One Roof

Retrieved on:

Thursday, January 25, 2024

Being Health has raised $5.4 million to date in funding from 18 Park and HDS Capital.

Key Points:

Being Health has raised $5.4 million to date in funding from 18 Park and HDS Capital.
Being Health offers a multi-dimensional approach and provides access to a diversity of evidence-based treatments to patients experiencing anxiety, depression, trauma, and stress.
“More and more Americans are grappling with mental health conditions, with far too many feeling overwhelmed by the burden of navigating their own care.
“We are creating a new standard for modern mental health care and are developing an ecosystem for the future delivery of novel treatments as they become FDA-approved.”

Pelago Expands C-Suite with Top Industry Talent to Position Company for Next Phase of Growth

Retrieved on:

Thursday, January 25, 2024

Additionally, Ed Daley has been promoted to Chief Commercial Officer, and Paige Swanepoel has been promoted to Chief Marketing Officer.

Key Points:

Additionally, Ed Daley has been promoted to Chief Commercial Officer, and Paige Swanepoel has been promoted to Chief Marketing Officer.
Dr. Glasner will oversee Pelago’s clinical research programs and ROI validation, and support product development from a clinical perspective.
His experience includes business planning, partnership development, and client growth and management as well as building and mentoring high performing teams.
Pelago is revolutionizing substance use management and leading the industry with its 3x ROI and 100% fees-at-risk business model, based on validated clinical outcomes and performance metrics.

LifeStance Appoints Dr. Ujjwal Ramtekkar as Chief Medical Officer

Retrieved on:

Friday, January 19, 2024

Family, Patient, Maryville University, Psychotherapy, Health, Life, Harvard Medical School, Psychiatry, University, Mental health, Teladoc Health, MBA, Child, Organization, Adolescence, Nursing

SCOTTSDALE, Ariz., Jan. 19, 2024 /PRNewswire/ -- LifeStance Health , one of the nation's largest providers of virtual and in-person outpatient mental healthcare, today announced that Dr. Ujjwal Ramtekkar will join the company as Chief Medical Officer, effective January 22, 2024.

Key Points:

SCOTTSDALE, Ariz., Jan. 19, 2024 /PRNewswire/ -- LifeStance Health , one of the nation's largest providers of virtual and in-person outpatient mental healthcare, today announced that Dr. Ujjwal Ramtekkar will join the company as Chief Medical Officer, effective January 22, 2024.
"Dr. Ramtekkar is an experienced physician executive with a demonstrated track record of driving exceptional patient and clinical outcomes," said Ken Burdick, Chairman and CEO, LifeStance.
Additionally, Dr. Ramtekkar is an adjunct clinical professor of psychiatry at University of Missouri-Columbia School of Medicine.
Dr. Patel-Dunn will work closely with Dr. Ramtekkar to ensure a seamless transition.